Wednesday, May 20, 2020 4:51:55 AM
LIONS BAY depends - like many others - on SARS-CoV-2 research
)
Lions Bay target preparing for COVID vaccine study
2020-05-14 12:42 ET - News Release
Mr. Jeremy Poirier reports
LIONS BAY MINING ANNOUNCES UPDATE ON ACQUISITION TARGET BIOVAXYS INITIATING A SARS-COV-2 VACCINE STUDY AND DEFINITIVE AGREEMENT
Lions Bay Mining Corp. has been informed that BioVaxys LLC is in the process of preparing to launch a preclinical study of its proprietary vaccine for SARS-CoV-2, the virus that causes COVID-19. Lions Bay recently announced entering into a non-binding letter of intent dated April 17, 2020, to acquire BioVaxys, a private Delaware corporation that is developing viral and oncology vaccine platforms for SARS-CoV-2 and various cancers.
https://www.stockwatch.com/News/Item?bid=Z-C%3aLBM-2906073&symbol=LBM®ion=C
) Lions Bay target preparing for COVID vaccine study
2020-05-14 12:42 ET - News Release
Mr. Jeremy Poirier reports
LIONS BAY MINING ANNOUNCES UPDATE ON ACQUISITION TARGET BIOVAXYS INITIATING A SARS-COV-2 VACCINE STUDY AND DEFINITIVE AGREEMENT
Lions Bay Mining Corp. has been informed that BioVaxys LLC is in the process of preparing to launch a preclinical study of its proprietary vaccine for SARS-CoV-2, the virus that causes COVID-19. Lions Bay recently announced entering into a non-binding letter of intent dated April 17, 2020, to acquire BioVaxys, a private Delaware corporation that is developing viral and oncology vaccine platforms for SARS-CoV-2 and various cancers.
https://www.stockwatch.com/News/Item?bid=Z-C%3aLBM-2906073&symbol=LBM®ion=C
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
